CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.

@article{Stuhlmller2010CD11cAA,
  title={CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.},
  author={Bruno Stuhlm{\"u}ller and Thomas Haeupl and Mario Hernandez and Andreas Gr{\"u}tzkau and R J Kuban and Nitin Tandon and Jeffrey W Voss and Jochen Salfeld and Raimund W. Kinne and Gerd ‐ R{\"u}diger Burmester},
  journal={Clinical pharmacology and therapeutics},
  year={2010},
  volume={87 3},
  pages={311-21}
}
We performed transcription profiling using monocytes to identify predictive markers of response to anti-tumor necrosis factor (anti-TNF) therapy in patients with rheumatoid arthritis (RA). Several potential predictors of response were identified, including CD11c. Validation in samples from independent cohorts (total of n = 27 patients) using reverse transcription-PCR confirmed increased expression of CD11c in responders to adalimumab (100% sensitivity; 91.7% specificity, power 99.6%; alpha = 0… CONTINUE READING
34 Citations
45 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis

  • Liu
  • Mol. Med
  • 2008

Iga rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis

  • F Bobbio-Pallavicini
  • Ann. Rheum. Dis
  • 2007

Similar Papers

Loading similar papers…